Table 2.
Procedural data and outcomes of ARVC patients undergoing catheter ablation.
| Study | Size, n | PT, h | FT, min | VT noninducibility post-ablation | Major complications, n | FU, months | AAD after ablation | VT free, n | Death (n) | HT, n |
| Data are presented as mean ± SD or n (%). ARVC: arrhythmogenic right ventricular cardiomyopathy; DVT: deep venous thrombosis; FT: fluoroscopy time; FU: follow-up; NR: not reported; PT: procedural time; RV: right ventricular; VT: ventricular tachycardia; HT: heart transplantation. *Indicating the comparative studies of combined endo-epicardial ablation versus endocardial-only ablation; †indicating the follow-up time in whole population. | ||||||||||
| Epicardial ± endocardial ablation | ||||||||||
| Aras 2019[16] | 11 | 4.1 | 6.5 | 8 (72.7%) | 0 | 14.8 ± 4.0 | 11 (100%) | 9 (81.8%) | 0 | 0 |
| Laredo 2019*[17] | 4 | NR | NR | 3 (75.0%) | 0 | 37.2 ± 27.6 | 3 (75.0%) | 4 (100%) | 0 | 0 |
| Mathew 2019*[18] | 21 | 5.0 | 20.0 | NR | 1 (pericardial tamponade%) | 50.8† | NR | NR | NR | NR |
| Santangeli 2019*[19] | 23 | NR | NR | 23 (100.0%) | 1 (RV laceration%) | 46.2 ± 17.9 | NR | 19 (82.6%) | 0 | 0 |
| Souissi 2018*[20] | 9 | NR | NR | NR | 1 (intestinal perforation%) | 64 ± 51† | 9 (100%) | NR | NR | 0 |
| Berruezo 2017[7] | 34 | NR | NR | 31 (91.2%) | 2 (pericardial tamponade%) | 32.2 ± 21.8 | 21 (51.2%) | 28 (82.4%) | 1 | NR |
| Müssigbrodt 2017*[9] | 22 | 3.4 | 41.8 | 19 (86.4%) | NR | 31.1 ± 27.4† | 19 (86.4%) | 13 (59.1%) | NR | NR |
| Wei 2017*[6] | 17 | NR | NR | 17 (100%) | 0 | 71.4 ± 45.7† | NR | 12 (70.6%) | 0 | 0 |
| Berte 2016*[21] | 4 | NR | NR | 3 (75.0%) | NR | 12.8 ± 8.7 | NR | 3 (75.0%) | 0 | 0 |
| Philips 2015[22] | 30 | NR | 82.2 | 29 (96.7%) | 1 (acute pericarditis%) | 19.7 ± 11.7 | 10 (33.3%) | 22 (73.3%) | 0 | 0 |
| Santangeli 2015*[8] | 39 | NR | NR | NR | 5 (2 DVT, 1 pericardial effusion, 1 RV puncture, 1 constrictive pericarditis%) |
56 ± 44† | NR | 30 (76.9%) | NR | NR |
| Philips 2012*[23] | 23 | NR | NR | NR | 2 (1 death, 1 delayed myocardial infarction%) |
88.3 ± 66† | 9 (39.1%) | 15 (65.2%) | 1 | 0 |
| Bai 2011*[24] | 26 | 5.3 | 65.9 | 26 (100.0%) | 0 | 40.8 ± 10.3 | 8 (30.8%) | 22 (84.6%) | 0 | 0 |
| Schmidt 2010[25] | 13 | NR | NR | 7 (53.8%) | NR | 12.1 | NR | 8 (61.5%) | NR | NR |
| Garcia 2009[26] | 13 | NR | NR | 11 (84.6%) | 0 | 18.3 ± 12.7 | 11 (84.6%) | 10 (76.9%) | 0 | 1 |
| Summary | 289 | - | - | 177/197 (89.8%) | 13/250 (5.2%) | - | 101/172 (58.7%) | 195/259 (75.3%) | 2/185 (1.1%) | 1/160 (0.6%) |
| Endocardial-only ablation | ||||||||||
| Laredo 2019*[17] | 19 | NR | NR | 8 (42.1%) | 0 | 62.4 ± 39.6 | 17 (89.5%) | 17 (89.5%) | 3 | 3 |
| Mathew 2019*[18] | 26 | 4.2 | 13.5 | NR | 0 | 50.8† | NR | NR | NR | NR |
| Santangeli 2019*[19] | 9 | NR | NR | 9 (100.0%) | 0 | 55.2 ± 18.7 | NR | 7 (77.8%) | 0 | 0 |
| Souissi 2018*[20] | 40 | NR | NR | NR | 2 (1 tamponade and hemothorax, 1 femoral arterio-venous fistula%) |
64 ± 51† | 39 (97.5%) | NR | NR | 2 |
| Müssigbrodt 2017*[9] | 23 | 2.7 | 30.2 | 19 (82.6%) | NR | 31.1 ± 27.4† | 19 (82.6%) | 13 (56.5%) | NR | NR |
| Wei 2017*[6] | 31 | NR | NR | 22 (71.0%) | 0 | 71.4 ± 45.7† | NR | 11 (35.5%) | 4 | 1 |
| Berte 2016*[21] | 3 | NR | NR | 3 (100.0%) | NR | 24.7 ± 11.0 | NR | 3 (100.0%) | 0 | 0 |
| Santangeli 2015*[8] | 23 | 1.3 | NR | NR | 0 | 56 ± 44† | NR | 14 (60.9%) | NR | NR |
| Hrosˇova' 2012[27] | 9 | 3.3 | 32.0 | 8 (88.9%) | NR | 52 ± 31 | 1 (11.1%) | 8 (88.9%) | 0 | 0 |
| Philips 2012*[23] | 64 | NR | NR | NR | 0 | 88.3 ± 66† | 39 (60.9%) | 29 (45.3%) | 0 | 0 |
| Bai 2011*[24] | 23 | 3.9 | 51.3 | 23 (100.0%) | 0 | 39.2 ± 3.7 | 18 (78.3%) | 12 (52.2%) | 0 | 0 |
| Nair 2011[28] | 15 | NR | NR | 13 (86.7%) | 0 | 25 ± 16 | 15 (100%) | 13 (86.7%) | 0 | 0 |
| Nogami 2008[29] | 18 | 3.6 | NR | 8 (44.4%) | NR | 61 ± 38 | 13 (72.2%) | 12 (66.7%) | 3 | NR |
| Dalal 2007[30] | 24 | NR | NR | 10 (41.7%) | 1 (death%) | 32 ± 36 | 20 (83.3%) | 4 (16.7%) | 1 | 2 |
| Yao 2007[4] | 32 | 3.4 | 42.0 | 24 (75.0%) | 0 | 28.6 ± 16 | 23 (71.9%) | 26 (81.3%) | 0 | 0 |
| Satomi 2006[31] | 17 | NR | NR | 15 (88.2%) | 0 | 26 ± 15 | 9 (52.9%) | 13 (76.5%) | 0 | 0 |
| Miljoen 2005[32] | 11 | 3.5 | 23.0 | 8 (72.7%) | 0 | 36 | 7 (63.6%) | 5 (45.5%) | 1 | NR |
| Verma 2005[33] | 22 | NR | 83.0 | 18 (81.8%) | 1 (pericardial tamponade%) | 37 | 22 (100%) | 14 (63.6%) | 0 | 0 |
| Marchlinski 2004[34] | 19 | 4.2 | NR | 14 (73.7%) | 0 | 27 ± 22 | NR | 17 (89.5%) | NR | 1 |
| Summary | 428 | - | - | 202/275 (73.5%) | 4/375 (1.1%) | - | 242/317 (76.3%) | 218/362 (60.2%) | 12/297 (4.0%) | 9/327 (2.8%) |